Acute Myocardial Infarction With Hyperoxemic Therapy (AMIHOT) A Prospective, Randomized Trial of Intracoronary Hyperoxemic Reperfusion After Percutaneous Coronary Intervention by O’Neill, William W. et al.
H
d
m
t
r
F
d
P
d
C
#
N
Journal of the American College of Cardiology Vol. 50, No. 5, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PCLINICAL RESEARCH Clinical Trials
Acute Myocardial Infarction
With Hyperoxemic Therapy (AMIHOT)
A Prospective, Randomized Trial of Intracoronary
Hyperoxemic Reperfusion After Percutaneous Coronary Intervention
William W. O’Neill, MD,* Jack L. Martin, MD,† Simon R. Dixon, MBCHB,‡
Antonio L. Bartorelli, MD,§ Daniela Trabattoni, MD,§ Pranobe V. Oemrawsingh, MD,
Douwe E. Atsma, MD, Michael Chang, MD,¶ William Marquardt, MD,¶ Jae K. Oh, MD,#
Mitchell W. Krucoff, MD,** Raymond J. Gibbons, MD,# J. Richard Spears, MD,††
for the AMIHOT Investigators
Miami, Florida; Bryn Mawr, Pennsylvania; Royal Oak and Detroit, Michigan; Milan, Italy;
Leiden, the Netherlands; Sacramento, California; Rochester, Minnesota; and Durham, North Carolina
Objectives This study sought to determine whether hyperoxemic reperfusion with aqueous oxygen (AO) improves recovery of
ventricular function after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
Background Hyperbaric oxygen reduces myocardial injury and improves ventricular function when administered during
ischemia-reperfusion.
Methods In a prospective, multicenter study, 269 patients with acute anterior or large inferior AMI undergoing primary or
rescue PCI (24 h from symptom onset) were randomly assigned after successful PCI to receive hyperoxemic
reperfusion (treatment group) or normoxemic blood autoreperfusion (control group). Hyperoxemic reperfusion
was performed for 90 min using intracoronary AO. The primary end points were final infarct size at 14 days,
ST-segment resolution, and  regional wall motion score index of the infarct zone at 3 months.
Results At 30 days, the incidence of major adverse cardiac events was similar between the control and AO groups (5.2%
vs. 6.7%, p  0.62). There was no significant difference in the incidence of the primary end points between the
study groups. In post-hoc analysis, anterior AMI patients reperfused 6 h who were treated with AO had a
greater improvement in regional wall motion ( wall motion score index  0.54 in control group vs. 0.75 in AO
group, p  0.03), smaller infarct size (23% of left ventricle in control group vs. 9% of left ventricle in AO group,
p  0.04), and improved ST-segment resolution compared with normoxemic controls.
Conclusions Intracoronary hyperoxemic reperfusion was safe and well tolerated after PCI for AMI, but did not improve re-
gional wall motion, ST-segment resolution, or final infarct size. A possible treatment effect was observed in ante-
rior AMI patients reperfused 6 h of symptom onset. (J Am Coll Cardiol 2007;50:397–405) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.099o
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Syperbaric oxygen improves ventricular function and re-
uces tissue injury when administered during evolving
yocardial infarction (1,2). Experimental data suggest that
his effect is mediated, in part, by decreasing tissue edema,
educing formation of lipid peroxide radicals, altering nitric
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iologico Monzino, University of Milan, Milan, Italy; Leiden University Medical
enter, Leiden, the Netherlands; ¶Mercy General Hospital, Sacramento, California;
Mayo Clinic, Rochester, Minnesota; **Duke Clinical Research Institute, Durham,
orth Carolina; and ††Wayne State University, Detroit, Michigan. Drs. O’Neill and 2xide synthase expression, and inhibition of leukocyte ad-
erence and plugging in the microcirculation (3–7). How-
See page 406
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Hyperoxemic Reperfusion in AMI July 31, 2007:397–405ever, use of hyperbaric oxygen
chambers is impractical for pa-
tients with acute myocardial in-
farction (AMI). Recently, a
novel site-specific method for
achieving regional hyperoxemia
has been developed using infu-
sion of blood mixed with aque-
ous oxygen (AO) (8). In experi-
mental models, intracoronary
AO hyperoxemic reperfusion has
been shown to improve micro-
vascular flow and left ventricular
unction and to reduce infarct size when administered after
oronary reperfusion (8–11). In a previous study we showed
hat hyperoxemic reperfusion using this technique was safe
nd feasible after primary percutaneous coronary interven-
ion (PCI) for AMI (12). More recently, 2 small clinical
tudies have shown that treatment with AO in patients with
nterior AMI improves left ventricular function and remod-
ling (13,14). Accordingly, the present study was designed
o determine whether hyperoxemic reperfusion with AO
ould improve ventricular function and microcirculatory
ow, or limit infarct size after primary or rescue PCI for
MI.
ethods
tudy population. From January 2002 to December 2003,
69 patients with AMI were randomly assigned to PCI with
r without adjunctive hyperoxemic reperfusion. Patients
ere eligible for enrollment up to 24 h from symptom onset.
ll patients had chest pain 30 min duration with ST-
egment elevation 1 mm in 2 contiguous leads. Patients
ith inferior AMI were required to have 1 mm reciprocal
T-segment depression in 2 precordial leads (V1 through
4). Clinical exclusion criteria were cardiogenic shock or
equirement for an intra-aortic balloon pump before or
uring PCI, coronary artery bypass surgery within 1 month,
evere cardiac valvular stenosis, pericardial disease, cardio-
yopathy, severe pulmonary disease with an arterial pO2
80 mm Hg on supplemental oxygen, and pregnancy.
ngiographic exclusion criteria were Thrombolysis In Myo-
ardial Infarction (TIMI) flow grade 3 in the infarct vessel
t initial angiography, saphenous vein graft culprit lesion,
ignificant left main disease (50% diameter stenosis),
nfarct related artery supplying a small amount of myocar-
ium, inability to stent the culprit lesion, and TIMI flow
rade 2 after PCI. The study was approved by the
nstitutional review board at each center. Written informed
onsent was obtained from each patient before enrollment.
ardiac catheterization and coronary intervention. All
atients received aspirin 300 mg orally, intravenous heparin
,000 U, and low-flow nasal oxygen before cardiac cathe-
erization. Coronary intervention was performed using stan-
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
AO  aqueous oxygen
PCI  percutaneous
coronary intervention
RWMSI  regional wall
motion score index
TIMI  Thrombolysis In
Myocardial Infarctionard equipment and techniques. Heparin was administered Co maintain the activated clotting time 250 s. All patients
ere treated with stent implantation. Glycoprotein receptor
nhibitors were administered at the operator’s discretion.
yperoxemic reperfusion. The study randomization was
erformed after completion of PCI. Patients were required
o have TIMI flow grade 2 or 3 after PCI with no evidence
f coronary dissection. Study allocations were assigned by
he research study coordinator, using sequentially num-
ered, opaque, sealed envelopes. The study assignments
ere generated from a master computer-generated random-
zation list, unique for each study center.
Hyperoxemic reperfusion was performed for 90 min
sing a custom extracorporeal circuit using AO (TherOx
nc., Irvine, California). Details of the Aqueous Oxygen
ystem have been previously reported (12). Blood for the
O system circuit was drawn from the sidearm of a 9-F
rterial sheath in a coaxial configuration, or alternatively a
-F sheath placed in the contralateral femoral or radial
rtery, and was mixed with AO in a polycarbonate chamber
o achieve an elevated pO2 of 760 to 1,000 mm Hg.
yperoxemic blood was delivered to the patient via a 5.3-F
ntracoronary infusion catheter (Tracker-38, Target Thera-
eutics, Fremont, California) positioned in the proximal
egment (1 to 2 cm) of the infarct-related artery (Fig. 1).
he blood flow rate was 75 ml/min. During hyperoxemic
eperfusion, the systemic arterial pO2 was measured every
0 min, and the infusion of AO was adjusted accordingly.
ata management and analysis. Study data, collected
rospectively by research coordinators, were verified against
ource documentation by independent trial monitors. An
ndependent committee, blinded to treatment assignment,
djudicated all adverse clinical events. All investigators had
ccess to study data.
chocardiographic analysis. Regional left ventricular
unction was measured by serial contrast 2-dimensional
chocardiography. Studies were performed immediately af-
er PCI (before AO infusion), at 24 h, at 1 month, and at
months. For the baseline study, patients were supine; for
ll other studies, patients were placed in the left lateral
ecubitus position. Echocardiographic imaging was per-
ormed with commercially available equipment. Studies
ere recorded on super-VHS tape and analyzed at the
ayo Clinic Echocardiographic Core Laboratory. Left
entricular wall motion was assessed using a 16-segment
odel according to the recommendation of the American
ociety of Echocardiography (15). Segments were graded as
 normal, 2  hypokinetic, 3  akinetic, and 4 
yskinetic. The regional wall motion score index (RWMSI)
f the infarct zone was derived by the formula: RWMSI 
um of segment scores/number of abnormal segments. The
RWMSI of the infarct zone was calculated as the differ-
nce in the RWMSI between the baseline and 3-month
tudy. If the 3-month study was not evaluable, the 1-month
all motion score was used to calculate the RWMSI.
alculations were performed off line by 2 observers blinded
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July 31, 2007:397–405 Hyperoxemic Reperfusion in AMIo clinical details and treatment assignment. In the event of
isagreement, a third observer was asked to adjudicate the
ndings.
T-segment resolution. Continuous electrocardiographic
onitoring was performed with Northeast Monitoring
EMON 180 12-lead digital electrocardiographic mon-
tors placed at the time of enrollment. Standard 12-lead
lectrocardiograms were acquired every 60 s on 128-MB
ash RAM cards. The Duke method of continuously
pdated ST-segment recovery analysis was performed by
he ECG Core Laboratory at the Duke Clinical Research
nstitute as has previously been described (16). Curve area
aken from the ST-segment level versus time trend curve
as measured as V-min above recovery ST-segment level
or 3 h from the time of randomization (end of PCI). Larger
urve areas represent worsened ischemic ST-segment
hanges, longer lasting ischemic ST-segment changes, or
oth. Curve areas of 0 represent no ischemic ST-segment
hanges over post-PCI recovery ST-segment levels over the
ime period (3 h) continuously monitored.
nfarct size. Final infarct size was measured 14 to 21 days
fter PCI using 99mTc-sestamibi single photon emission
omputed tomography imaging. Images were obtained with
ingle-head or multihead gamma cameras with images
cquired in a 64  64 matrix. All images were analyzed at
he Mayo Clinic Nuclear Core Laboratory using previously
escribed methods (17–19).
tudy end points and definitions. The primary safety end
oint was the incidence of death, reinfarction, target vessel
evascularization, and stroke at 30 days. The primary effi-
acy end points of the study were: 1) change in RWMSI of
he infarct zone at 3 months (WMSI); 2) ST-segment
urve area 3 h after PCI; and 3) final myocardial infarct size
t 14 to 21 days. Reinfarction was defined as the recurrence
Figure 1 Diagram of the AO System Circuit
AO  aqueous oxygen.f clinical symptoms or new electrocardiographic changes eccompanied by an increase in creatine kinase-MB levels
2 times baseline. Target vessel revascularization was de-
ned as urgent revascularization of the target vessel by either
CI or coronary artery bypass surgery. Patients assigned to
yperoxemic reperfusion who received 60 min AO ther-
py were considered failure-to-treat cases.
tatistical analysis plan. The study hypothesis was that
atients undergoing PCI for AMI would have improved
egional wall motion, improved (reduced) ischemic ST-
egment 3-h curve areas, and a reduction in infarct size
ompared with patients undergoing primary PCI alone. The
tudy was designed to detect the following differences with
0% power using a 1-sided significance level of 5%:
) 0.2-U improvement in RWMSI of the infarct zone;
) 50% improvement in ST-segment curve area; and 3) a
eduction in mean final infarct size of 5% of the left
entricle. The sample size estimation of 250 patients was
ased on analysis of each of the 3 efficacy end points, with
n assumed patient dropout rate of10%. Based on historic
ata and the above assumptions, it was calculated that 114
atients per group were required to detect a difference in
T-segment curve area or final infarct size, and 52 patients
er group were required to detect a difference in RWMSI
12,17,19). The primary efficacy end points were analyzed in
ll intent-to-treat patients who had evaluable studies. The
WMSI data were compared using the unpaired Student t
est. Before analysis, data were examined for baseline
ifferences to determine whether appropriate transforma-
ions were necessary. The ST-segment curve area data were
ighly skewed over the entire population, limiting the utility
f parametric analysis. Therefore, ST-segment data were
ompared by categorizing the area under the ST-segment
eviation time curve into 4 categories (0, 1 to 2,000, 2,000
o 5,000 and 5,000). Proportions of patients with areas in
ach of these intervals were compared between the study
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Hyperoxemic Reperfusion in AMI July 31, 2007:397–405roups using the Armitage chi-square test. Analysis of
nfarct size was performed using the Wilcoxon signed rank
est because of the skewed distribution of infarct size (18).
econdary analyses were also performed on prespecified
ubgroups, including age, prior thrombolytic therapy, in-
arct location, time-to-treatment, left ventricular ejection
raction, and baseline TIMI flow grade. Continuous vari-
bles were examined using the Student t test, whereas
ategorical data were evaluated using the chi-square test for
omogeneity. A p value of 0.05 was considered statisti-
ally significant. Statistical analysis was performed with the
CSS 2004 software package (Kaysville, Utah).
esults
linical data. A total of 289 patients were enrolled at 23
nvestigational sites in 3 countries. Of the 289 patients, 20
ere enrolled in a roll-in phase to familiarize the investiga-
ors with the infusion technique, and 269 were randomly
ssigned to PCI with or without hyperoxemic reperfusion
Fig. 2). Of the 269 randomized patients, 135 were assigned
o the control arm and 134 to the treatment arm. Of the 134
atients assigned to the treatment arm, 123 patients re-
eived 60-min hyperoxemic reperfusion. The baseline
linical characteristics of the 2 study groups were well
atched (Table 1).
ngiographic and procedural data. Approximately 90%
f patients in each study group had complete occlusion
TIMI flow grade 0 or 1) of the infarct-related artery at
nitial angiography (Table 2). All patients were treated with
Figure 2 Clinical Recruitment Algorithm
AO  aqueous oxygen; FTT  failure to treat (see text for definition); IABP  intra
MI  myocardial infarction; PCI  percutaneous coronary intervention; WMSI  watent implantation; 234 (87%) received a glycoprotein re-
eptor inhibitor. There was no significant difference in the
se of abciximab or eptifibatide between the study groups.
fter stent implantation, 92% of patients in the control
roup and 96% of patients in the AO group had TIMI flow
rade 3 in the infarct vessel.
yperoxemic reperfusion. Among the 134 patients ran-
omly assigned to receive hyperoxemic reperfusion after
tenting of the infarct-related artery, 117 (87%) completed
90-min AO infusion, 6 (4%) received a 60- to 90-min AO
nfusion, and 11 (8%) received 60 min AO therapy. Of
hese 11 patients, 8 received an incomplete infusion because
f technical issues with the AO system (most commonly a
inked line caused system shutdown), 1 patient had a low
aseline pO2 and was excluded from receiving therapy, 1
atient had the AO infusion halted to treat another lesion in
he infarct vessel, and 1 patient did not receive the infusion
ecause of a system malfunction. Hyperoxemic reperfusion
as well tolerated. No hemodynamic or electrical instability
as observed during the infusion.
dverse events. At 30 days, the primary safety end point
ad occurred in 5.2% of the control group and 6.7% of those
ssigned to hyperoxemic reperfusion (p  0.62) (Table 3).
ne patient developed stent thrombosis in the proximal left
nterior descending artery during the AO infusion. This
atient had significant disease at the ostium of the left
nterior descending artery that impaired antegrade flow into
he artery after the AO infusion catheter was positioned
ubselectively in the vessel. Further balloon dilatation was
erformed with a good anatomical result, and there were no
balloon pump;
ion score index.-aortic
ll mot
c
i
p
T
s
a
R
2
HF  c
401JACC Vol. 50, No. 5, 2007 O’Neill et al.
July 31, 2007:397–405 Hyperoxemic Reperfusion in AMIlinical sequelae. Patients in the AO group also had a higher
ncidence of vascular access complications than control
atients, mainly because of hematomas (6.0% vs. 3.0%).
his was most likely related to the larger sheaths used in
Clinical Characteristics of the Patients
Table 1 Clinical Characteristics of the Patie
Contro
(n 
Age, yrs (mean  SD) 60 
Age, yrs (median, IQR) 59 (3
Female 36 (2
Diabetes mellitus 15 (1
Hypertension 66 (4
Hyperlipidemia 56 (4
Current smoker 57 (4
Previous MI 14 (1
Previous PCI 10 (7
Previous CABG 2 (1
Previous CHF 3 (2
Prior thrombolytic therapy 21 (1
Anterior MI 76 (5
Killip class
I 127 (9
II 7 (5
III 1 (0
IV 0 (0
Time (median  IQR)*
From symptom onset to hospital
arrival (min)
120 
Door-to-balloon (min) 89.5 
From symptom onset to
reperfusion (min)
248 
Peak creatine kinase (IU/l) 2,610 
*Wilcoxon rank test. First balloon inflation was not recorded; door-to-b
AO  aqueous oxygen; CABG  coronary artery bypass grafting; C
infarction; PCI  percutaneous coronary intervention.
Angiographic and Procedural Data
Table 2 Angiographic and Procedural Data
C
Infarct-related artery
Left anterior descending coronary artery
Right coronary artery
Circumflex artery
Other
Initial diameter stenosis
Initial TIMI flow grade
0/1
2
3
Stent implanted
Glycoprotein IIb/IIIa inhibitor
Abciximab
Eptifibatide
Final diameter stenosis (%)
Final TIMI flow grade
0/1
2
3AO  aqueous oxygen; TIMI  Thrombolysis In Myocardial Infarction.ome patients in the AO group, and the requirement for
dditional anticoagulation during the 90-min infusion.
egional wall motion. Of the 269 randomized patients,
34 (87%) completed echocardiographic follow-up at 3
p AO Group
(n  134) p Value
60  13 0.99
60 (35–89)
36 (26.9%) 0.97
17 (12.7%) 0.69
71 (53.0%) 0.48
65 (54.2%) 0.18
58 (43.3%) 0.50
18 (13.4%) 0.44
16 (11.9%) 0.21
2 (1.5%) 0.99
3 (2.3%) 0.99
15 (11.2%) 0.29
81 (60.4%) 0.49
118 (88.1%) 0.23
13 (9.7%)
3 (2.2%)
0 (0.0%)
109  240 0.87
90.5  62.8 0.50
260  295.5 0.54
5 2,449  1,935 0.51
times were recorded using time of first contrast injection.
ongestive heart failure; IQR  interquartile range; MI  myocardial
Group
135)
AO Group
(n  134) p Value
6.3%) 81 (60.4%) 0.63
5.6%) 42 (31.3%)
.9%) 10 (7.5%)
.2%) 1 (0.7%)
1% 100  0% 0.12
9.7%) 117 (87.3%) 0.76
0.4%) 17 (12.4%)
.0%) 0 (0.0%)
00%) 134 (100%) 1.00
4.4%) 120 (89.5%) 0.46
1.1%) 77 (64.2%) 0.26
8.9%) 43 (35.9%) 0.26
10 0  10 0.90
.0%) 0 (0.0%) 0.13
.1%) 5 (3.7%)
1.9%) 129 (96.3%)nts
l Grou
135)
12
3–94)
6.7%)
1.1%)
8.9%)
5.5%)
2.2%)
0.4%)
.4%)
.5%)
.3%)
5.6%)
6.3%)
4.1%)
.2%)
.7%)
.0%)
180
73.5
231
1,98
alloonontrol
(n 
76 (5
48 (3
8 (5
3 (2
100 
121 (8
14 (1
0 (0
135 (1
114 (8
81 (7
33 (2
0 
0 (0
11 (8
124 (9
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Hyperoxemic Reperfusion in AMI July 31, 2007:397–405onths and had studies evaluable by the core laboratory.
he mean RWMSI of the infarct zone at baseline was
imilar between study groups (control 2.67  0.26 vs. AO
.64  0.30, p  NS). At 3 months, the RWMSI of the
nfarct zone was 0.57  0.48 in the control group and
0.62  0.53 in the AO group (p  0.24) (Fig. 3). In
econdary analysis, patients reperfused 6 h had a trend
oward a higher RWMSI in the AO group compared with
ontrols (Table 4). The interobserver variability of the
WMSI was 0.29  0.27.
T-segment resolution. Continuous digital electrocardio-
raphic data were available in 237 patients (88%). In the
verall patient group, the area under the ST-segment
eviation time curve for 0 to 3 h after PCI was similar in the
ontrol and AO groups (Fig. 4).
nfarct size. Two hundred forty-three patients (90%) had
nfarct size measured at follow-up. At 14 days, the median
nfarct size was 13% of the left ventricle in the control group
interquartile range 0 to 39) and 11% of the left ventricle in
he AO group (interquartile range 0 to 38) (p  0.30)
Fig. 5). In secondary analysis, patients with age 59.5
linical Data at 30 Days
Table 3 Clinical Data at 30 Days
Control Group
(n  135)
AO Group
(n  134) p Value
Death 2 (1.5%) 4 (3.0%) 0.45
Reinfarction 3 (2.2%) 3 (2.2%) 1.00
Target vessel
revascularization
3 (1.5%) 3 (1.5%) 1.00
Stroke 2 (1.5%) 1 (0.7%) 1.00
Composite end point (major
adverse cardiac event)
7 (5.2%) 9 (6.7%) 0.62
O  aqueous oxygen.
Figure 3 Echo Wall Motion Changes
Change in wall motion score index of the infarct zone at 3 months in patients ass
fusion (intent-to-treat analysis). Results are shown for the overall study group and
group; RWM  regional wall motion.ears, time to reperfusion6 h, and initial TIMI flow grade
had a smaller infarct size in the AO group compared with
ontrol patents (Table 5). A larger infarct size was observed
n the subgroup of patients reperfused 6 to 24 h who
eceived AO; however, this group had a higher proportion
f anterior MI and a longer mean time to reperfusion.
ost-hoc analysis. In post-hoc analysis, anterior AMI
atients reperfused 6 h who were treated with AO had a
reater improvement in regional wall motion (RWMSI 
0.54  0.49 in the control group vs. 0.75  0.57 in the
O group, p  0.03), more complete ST-segment resolu-
ion, and a smaller median infarct size (23% of left ventricle
n the control group [interquartile range 0 to 56] vs. 9% of
eft ventricle in the AO group [interquartile range 0 to 49],
 0.04), compared with normoxemic control patients
Figs. 3 to 5).
iscussion
n the present study, treatment with hyperoxemic reperfu-
ion after PCI for AMI did not result in improved regional
all motion, more complete ST-segment resolution, or
educed infarct size; however, the therapy was safe and well
olerated.
There are several possible explanations for why the
resent study failed to meet the primary efficacy end points.
irst, the trial had a broad window for enrollment and
ncluded patients presenting up to 24 h from symptom
nset. By comparison, most other studies evaluating ad-
uncts to reperfusion therapy have enrolled only patients
resenting within 6 h. The broad inclusion window used in
he present trial was based on data from an experimental
tudy in which pigs treated with AO 24 h after reperfusion
o undergo percutaneous coronary intervention with or without hyperoxemic reper-
ts with anterior acute myocardial infarction (MI) 6 h. AO  aqueous oxygenigned t
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July 31, 2007:397–405 Hyperoxemic Reperfusion in AMIad a significant improvement in left ventricular function
nd infarct size compared with control animals (11). How-
ver, it is likely that this animal model has relatively limited
pplicability to clinical patients presenting late in the course
f AMI. In addition, although a single randomized trial
howed myocardial salvage in patients treated with PCI
fter 12 h (20), 43% of patients in that trial had initial TIMI
ow grade 2 or 3, compared with only 11% with TIMI flow
rade 2 in this study (patients with TIMI flow grade 3 were
xcluded). Second, hyperoxemic reperfusion (or any adjunct
Figure 4 Changes in ST-Segment Elevation
The ST-segment resolution in patients assigned to undergo percutaneous coronary
under the ST-segment deviation vs. time curve 0 to 3 h after PCI; intent-to-treat an
myocardial infarction (MI) 6 h. A greater proportion of anterior MI patients in the
controls.
Change in Regional Wall Motion Score Index of
Table 4 Change in Regional Wall Motion Sc
Control Gro
(n  119
All patients 0.57 0.48
Age 59.5 yrs* 0.57 0.45
Age 59.5 yrs 0.57 0.51
Thrombolytic 0.45 0.51
No thrombolytic 0.59 0.47
Anterior MI 0.57 0.48
Nonanterior MI 0.57 0.49
Time to reperfusion 6 h 0.55 0.48
Time to reperfusion 6 to 24 h 0.62 0.49
LVEF 40% 0.56 0.47
LVEF 40% 0.58 0.49
Initial TIMI flow grade 0/1 0.56 0.45
Initial TIMI flow grade 2 0.69 0.66
*Median value for group. Data shown are mean  SD (n).
AO  aqueous oxygen; LVEF  left ventricular ejection fraction; MIherapy) may be unnecessary in selected patient subgroups,
uch as those with inferior infarction. Data from this trial,
nd other recent mechanical reperfusion studies, suggest
hat the final infarct size in inferior AMI patients treated
ith PCI is typically 10% of the left ventricular mass.
iven the smaller infarct size after mechanical reperfusion
er se in such patients, the effect of any adjunct therapy will
e very difficult to show without a very large number of
atients (19), and may not have any significant impact on
linical outcome. Third, the time delay to initiate hyperox-
ention (PCI) with or without hyperoxemic reperfusion (measured by the area
). Results are shown for the overall study group and patients with anterior acute
us oxygen (AO) group had improved ST-segment resolution compared with
nfarct Zone at 3 Months
dex of the Infarct Zone at 3 Months
AO Group
(n  115) p Value
0.62 0.53 (115) 0.24
0.66 0.56 (61) 0.16
0.57 0.49 (54) 0.49
0.36 0.48 (14) 0.30
0.65 0.53 (101) 0.19
0.67 0.55 (71) 0.13
0.53 0.49 (44) 0.35
0.69 0.55 (79) 0.06
0.47 0.47 (36) 0.11
0.58 0.49 (42) 0.45
0.64 0.55 (73) 0.22
0.61 0.54 (100) 0.21
0.66 0.49 (15) 0.44
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Hyperoxemic Reperfusion in AMI July 31, 2007:397–405mic reperfusion after PCI may have affected the potential
enefit of therapy. In an experimental study by Sterling et al.
1), no protection was observed when hyperbaric oxygen was
dministered late after reperfusion. Fourth, when regional
all motion abnormalities assessed by echocardiography
ere correlated with infarct size by sestamibi imaging in
MI patients treated with reperfusion therapy, recovery of
egional myocardial function was slower than that of the
erfusion defect (21). Regional myocardial function may
emain abnormal unless transmural ischemia is almost
ompletely reversed by reperfusion. Therefore, wall motion
nalysis at a longer follow-up period might have shown a
ore significant benefit from hyperoxemic therapy. Fi-
ally, one must also consider the possibility that the AO
nfusion as applied in this trial did not result in regional
yperoxemia or influence myocardial metabolism. Al-
Figure 5 Changes in Nuclear Infarct Size
Final infarct size at 14 days in patients assigned to undergo percutaneous corona
(intent-to-treat analysis). Results are shown for the overall study group and patient
Infarct Size at 14 Days
Table 5 Infarct Size at 14 Days
Control Gr
(n  12
All patients 13 26 (1
Age 59.5 yrs* 13 27 (6
Age 59.5 yrs 14 27 (5
Thrombolytic 10 26 (2
No thrombolytic 14 25 (1
Anterior MI 19 31 (7
Nonanterior MI 8 14 (5
Time to reperfusion 6 h 18 17 (8
Time to reperfusion 6 to 24 h 15 14 (3
LVEF 40% 30 26 (4
LVEF 40% 8 15 (7
Initial TIMI flow grade 0/1 13 26 (1
Initial TIMI flow grade 2 15 32 (1*Median value for group. Data shown are median  IQR (n).
Abbreviations as in Table 4.hough this has not been specifically evaluated in clinical
tudies, experimental data suggest that higher arterial
xygen levels do increase oxygen extraction and reduce
actate production, suggesting a favorable effect on isch-
mic myocardium (8,10,22).
ffect in anterior myocardial infarction <6 h. Although
yperoxemic reperfusion was not found to be beneficial in
he overall study group, a promising signal was identified in
nterior AMI patients who were treated within 6 h of
ymptom onset. In this group, there was a significant
mprovement in infarct size, ST-segment resolution, and
egional wall motion in patients who were treated with AO.
he fact that there was a consistent and parallel improve-
ent in microvascular reperfusion, regional function, and
nfarct size in the AO patients suggests that this was a
reatment effect rather than a result of chance alone.
rvention with or without hyperoxemic reperfusion
anterior myocardial infarction (MI) 6 h. AO  aqueous oxygen group.
AO Group
(n  121) p Value
11 28 (121) 0.30
7 20 (63) 0.02
17 30 (58) 0.11
15 29 (15) 0.44
11 28 (106) 0.31
21 35 (73) 0.31
7 14 (48) 0.39
14 17 (82) 0.04
23 18 (39) 0.02
20 30 (47) 0.08
7 20 (74) 0.43
16 27 (105) 0.43
0 10 (16) 0.06ry inte
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July 31, 2007:397–405 Hyperoxemic Reperfusion in AMIowever, given the limitations of subgroup analysis, these
bservations should be considered exploratory and therefore
eed to be confirmed in a prospective study.
tudy limitations. The main limitation of the study was
he small sample size. Although the trial was sufficiently
owered to show differences in each of the individual
fficacy end points, the study was too small to detect
reatment differences in patient subgroups. Second, inclu-
ion of patients presenting up to 24 h from symptom onset
as also a significant limitation as previously discussed.
hird, a small number of patients assigned to hyperoxemic
eperfusion did not receive a complete 90-min infusion of
O. Another potential limitation was that for patients with
issing echocardiographic data at 3 months, the wall
otion score from the 1-month study was used. Because
rogressive improvement in the wall motion score typically
ccurs up to 3 months from AMI, use of the 1-month value
ay underestimate any treatment effect. Finally, an impor-
ant methodological limitation of the study was inclusion of
co-primary end points, which is considered unusual with
ontemporary clinical trial design. However, at the time the
MIHOT (Acute Myocardial Infarction with HyperOx-
mic Reperfusion) trial was planned there was little consen-
us regarding the ideal surrogate end points in clinical trials
valuating new adjuncts to reperfusion therapy, and for this
eason 3 end points were selected.
onclusions
his study shown that hyperoxemic reperfusion after PCI
or AMI is safe and well tolerated but does not improve
egional wall motion, improve ST-segment resolution, or
educe final infarct size. In post-hoc analysis, a possible
reatment effect was observed in patients with anterior AMI
6 h. These data suggest that further investigation is
equired to determine whether hyperoxemic reperfusion will
mprove ventricular function or clinical outcome in anterior
nfarction.
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